South Africa: Chronic Kidney Disease Rates Have Dropped in People With HIV, but Late Diagnosis Remains a Serious Problem
[spotlight] People living with HIV are at an increased risk of developing several opportunistic infections and co-morbidities, including chronic kidney disease. Elri Voigt unpacks the complex effect that HIV has on the kidneys, how HIV and chronic kidney disease has evolved after the roll out of anti-retroviral treatment, and what the situation is now in the country for people living with HIV and chronic kidney disease. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - April 22, 2024 Category: African Health Tags: HIV-Aids and STDs Health and Medicine South Africa Southern Africa Source Type: news
Risk Prediction Model Accurate for Chronic Kidney Disease
FRIDAY, April 19, 2024 -- For individuals with moderate-to-severe chronic kidney disease (CKD), a model, KDpredict, can accurately predict the risk for kidney failure and death, according to a study published online April 15 in The BMJ.
Ping Liu,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 19, 2024 Category: Pharmaceuticals Source Type: news
Multidisciplinary Team Intervention Flops for Improving CKD Outcomes
(MedPage Today) -- A multi-pronged electronic health record-based population health management intervention failed to move the needle for slowing chronic kidney disease (CKD) progression, a cluster randomized trial showed.
Over a median follow... (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - April 15, 2024 Category: Primary Care Source Type: news
Metabolite in Red Meat Increases Kidney Disease Risk Metabolite in Red Meat Increases Kidney Disease Risk
Trimethylamine N-oxide could be a novel risk factor and intervention target for chronic kidney disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 11, 2024 Category: Consumer Health News Tags: Nephrology Clinical Summary Source Type: news
Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion
Transaction would give the pharmaceutical giant access to Alpine’s potential treatment for chronic kidney disease. (Source: Reuters: Health)
Source: Reuters: Health - April 10, 2024 Category: Consumer Health News Source Type: news
Roche and Alnylam present positive results from the Phase II KARDIA-2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled hypertension
The KARDIA-2 study met its primary endpoint demonstrating additive, placebo-adjusted systolic blood pressure reductions of up to 12.1 mmHgat month three. These results were statistically significant and clinically meaningfulZilebesiran demonstrated an encouraging safety and tolerability profile when added to standard of care antihypertensives Basel, 7 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam today released detailed results from the Phase II KARDIA-2 study evaluating the efficacy and safety of a single subcutaneous dose of zilebesiran when added to one of three standard of care (SOC) antihypertensives. T...
Source: Roche Investor Update - April 7, 2024 Category: Pharmaceuticals Source Type: news
Groups Ask WHO to Recognize Chronic Kidney Disease Threat Groups Ask WHO to Recognize Chronic Kidney Disease Threat
Three international nephrology organizations call for World Health Organization recognition of CKD as a major noncommunicable mortality driver.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 5, 2024 Category: Consumer Health News Tags: Nephrology Source Type: news
EHR-Based Algorithm Does Not Cut Hospitalization in Kidney Dysfunction Triad
THURSDAY, April 4, 2024 -- For patients with the triad of chronic kidney disease, type 2 diabetes, and hypertension, the use of an electronic health record-based algorithm and intervention does not result in reduced hospitalization at one year,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 4, 2024 Category: Pharmaceuticals Source Type: news
Primary Care Strategy Fails to Reduce Kidney-Dysfunction Triad Hospitalizations
(MedPage Today) -- Using a personalized algorithm to identify primary care patients with chronic kidney disease (CKD), type 2 diabetes, and hypertension (the kidney-dysfunction triad) -- plus practice facilitators to help providers deliver guideline... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 4, 2024 Category: Cardiology Source Type: news
CKD Progress Risk Increased Even if Albuminuria Range Normal CKD Progress Risk Increased Even if Albuminuria Range Normal
A linear increase in the risk for chronic kidney disease progression is observed even in albuminuria ranges (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 2, 2024 Category: Consumer Health News Tags: Nephrology Source Type: news
CKD Progression Risk Up With Increasing Albuminuria in Normal Range
MONDAY, April 1, 2024 -- For people with chronic kidney disease (CKD) and normoalbuminuria, the risk for CKD progression increases with higher levels of albuminuria, according to a study published online April 2 in the Annals of Internal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 1, 2024 Category: Pharmaceuticals Source Type: news
Once-Rejected Drug Now FDA Approved for CKD-Related Anemia
(MedPage Today) -- The FDA approved vadadustat (Vafseo) for chronic kidney disease (CKD)-related anemia in adults who have been on dialysis for at least 3 months, developer Akebia Therapeutics announced on Wednesday.
"Patients receiving maintenance... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 28, 2024 Category: Hematology Source Type: news
Study Reveals Glucagon Receptors' Role in Renal Health Study Reveals Glucagon Receptors' Role in Renal Health
In findings with implications for future therapies in chronic kidney disease, mouse studies show a protective effect of glucagon receptor signaling in the kidney.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 28, 2024 Category: Consumer Health News Tags: Nephrology Source Type: news
Two years after initial rejection, Akebia ’s anemia drug finally gets FDA approval
The FDA approved the Cambridge biotech's drug vadadustat for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 28, 2024 Category: Biotechnology Authors: Hannah Green Source Type: news
FDA Approves Vafseo (vadadustat) for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
CAMBRIDGE, Mass., March 27, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 27, 2024 Category: Drugs & Pharmacology Source Type: news
